25/10/2014 01:40:27 Free Membership Login

Cubist News (NASDAQ:CBST)

DateTimeSource
Headline
10/21/20144:00PMBWCubist Reports Third Quarter 2014 Financial Results
Total Net Revenues of $309.2 Million, Up 16% Over Q3 2013 Non-GAAP Adjusted Operating Income of $99.1 Million; GAAP Operating Income of $67.8 Million Non-GAAP Diluted EPS of $0.58; GAAP Diluted EPS of $0.29 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the third quarter ended September 30, 2014... More...>>
10/20/20147:30AMBWCubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer
Michael W. Bonney to Become Non-Executive Chair of the Board of Directors Kenneth M. Bate to Become Lead Independent Director Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that its Board of Directors has selected Robert J. Perez as the Company’s Chief Executive Officer, effective January 1, 2015. Perez... More...>>
10/14/20149:00AMBWCubist to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014
Earnings Conference Call & Webcast at 5:00 pm ET Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its third quarter 2014 financial results at 4:00 p.m. ET on Tuesday, October 21, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET... More...>>
10/08/20148:30AMBWCubist to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it will present new data from a phase 1 safety and pharmacokinetic study of fidaxomicin in children with Clostridium difficile-associated diarrhea (CDAD) at IDWeek 2014, being held October 8-12 in Philadelphia. These new data will be featured as a late-breaking... More...>>
09/30/20148:30AMBWCubist to Present New Data on Antibiotics Portfolio at IDWeek 2014
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will present new data from its antibiotics portfolio at IDWeek 2014, October 8-12, in Philadelphia, PA. Presentations of these data are important as new antibiotics are needed for the growing global public health issue of serious and sometimes life-threatening... More...>>
09/18/20144:30AMBWCubist Announces Continued Global Expansion with Opening of International Headquarters in Zurich
Company reinforces its commitment to global public health with more investment in antibiotic R&D than any company worldwide With resistant bacterial infections resulting in an estimated 25,000 deaths in the European Union and 23,000 deaths in the United States annually, the issues of rising antibiotic resistance and... More...>>
09/18/20144:30AMBWCubist annonce la poursuite de son expansion mondiale avec l'ouverture de son siège international à Zurich
La société renforce son engagement pour la santé publique dans le monde, avec davantage d'investissements dans les activités de R et D sur les antibiotiques que toutes les autres sociétés à l'échelle internationale Compte tenu des infections bactériennes résistantes qui entraînent environ 25 000 décès dans... More...>>
09/18/20144:30AMBWCubist setzt weltweite Expansion mit Eröffnung seines internationalen Hauptsitzes in Zürich fort
Cubist stellt sein Engagement für die öffentliche Gesundheit weltweit mit von keinem anderen Unternehmen übertroffenen Investitionen in Antibiotika-Forschung und -Entwicklung unter Beweis Jährlich sterben schätzungsweise 25.000 Menschen in der Europäischen Union und 23.000 in den USA an Infektionen, die durch resistente... More...>>
08/26/20148:30AMBWCubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents & Chemotherapy ...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington, D.C. Data highlighted will offer insights into Cubist’s commitment to identifying treatments for drug-resistant Gram-positive... More...>>
08/25/20149:00AMBWCubist to Present at Morgan Stanley Global Healthcare Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Mike Bonney, Cubist’s CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, to discuss the company’s business activities, financial outlook, and current news. The presentation will be held at the Grand Hyatt New... More...>>
08/22/20147:30AMBWCubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the European Medicines Agency (EMA) has accepted for review the Company’s Marketing Authorization Application (MAA) for its investigational antibiotic ceftolozane/tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated... More...>>
08/22/20147:30AMBWCubist annonce l’acceptation par l’EMA du dossier de demande d’autorisation de mise sur le marché du ceftolozane/tazob...
Cubist Pharmaceuticals, Inc. (NASDAQ : CBST) a annoncé aujourd’hui que l’Agence européenne des médicaments (EMA) a accepté d’étudier la demande d’autorisation de mise sur le marché (MAA) de la société pour son candidat antibiotique ceftolozane/tazobactam. Cubist recherche l’approbation du ceftolozane/tazobactam... More...>>
08/22/20147:30AMBWCubist meldet Annahme des Marktzulassungsantrags für Ceftolozan/Tazobactam bei der EMA
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) gab heute bekannt, dass die Europäische Arzneimittelagentur (EMA) den Antrag des Unternehmens auf das Inverkehrbringen (MAA) seines Prüfantibiotikums Ceftolozan/Tazobactam zur Prüfung angenommen hat. Cubist beantragt damit die Zulassung von Ceftolozan/Tazobactam für die Behandlung... More...>>
08/08/20145:47PMBWCubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL ...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling nine lots of CUBICIN® (daptomycin for injection) to the user level following complaints of foreign particulate matter in reconstituted vials. The administration of particulate matter, if present in an intravenous drug, poses a potential... More...>>
08/06/20148:42AMBWCubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL sin...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling certain lots of CUBICIN® (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Please click here for the list of affected CUBICIN lot information... More...>>
08/06/20148:00AMBWCubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL sin...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling certain lots of CUBICIN® (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Please click here for the list of affected CUBICIN lot information... More...>>
08/05/20148:30AMBWCubist’s Once-daily SIVEXTRO™ (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulati...
SIVEXTRO is a short, six-day course of therapy to treat serious skin infections, including those caused by MRSA Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announces SIVEXTRO™ (tedizolid phosphate) indicated for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) is now available in the... More...>>
07/28/20149:00AMBWCubist to Present at August Investor Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will discuss Cubist’s business activities and financial outlook at investor conferences during August 2013. On Wednesday, August 6, Robert Perez, Cubist President and COO, and Michael Tomsicek, Cubist SVP and Chief Financial Officer... More...>>
07/22/20144:00PMBWCubist Reports Second Quarter 2014 Financial Results
Total Net Revenues of $294.4 Million, Up 14% Over Q2 2013 Non-GAAP Adjusted Operating Income of $41.4 Million; GAAP Operating Income of $42.2 Million Non-GAAP Diluted EPS of $0.23; GAAP Diluted EPS of $0.30 Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the second quarter ended June 30, 2014. The... More...>>
07/15/20149:00AMBWCubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014
Earnings Conference Call & Webcast at 5:00 pm ET Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its second quarter 2014 financial results at 4:00 p.m. ET on Tuesday, July 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq cbst141025 01:40